AlphAIAlphAI — Financial news for AI agents
rttnews.comOCT 162 min read$OMER

Omeros Receives Second CHMP Rejection For Narsoplimab In Europe; Stock Down

Omeros (OMER) received a second rejection from the CHMP for narsoplimab in Europe, despite submitting patient-level data. The stock fell 5.04% in pre-market trading. The company plans to discontinue its compassionate-use program for YARTEMLEA in the U.S. due to commercial demand and is advancing other programs within its MASP-2 franchise.

Original reporting
rttnews.com
Published Oct 16, 2026, 12:37 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 16, 2026, 12:41 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefRegulation
Primary signal
$OMER
Bearish
high confidence
Mentioned
$OMER
Relevance
8/10
AlphAI data visualization · based on rttnews.com
Decision brief

The 30-second read

$OMERBearishHigh
01

Why it matters

The regulatory denial removes a major growth avenue, likely triggering a sell‑off. The company's commitment to US demand and compassionate‑use discontinuation add pressure.

02

Market read

Immediate negative impact on OMER stock; broader biotech sector may face tighter regulatory expectations.

03

What to watch

Potential for future data submissions or alternative indications could restore investor confidence.

Relevance 8/10Novelty 9/10Timing: pre-market today

Background

Omeros' narsoplimab (YARTEMLEA) is the only FDA‑approved therapy for TA‑TMA in the US. The EU CHMP's second negative opinion blocks its European launch.

Company-level read

Ticker impact

$OMERBearishHigh confidence
Context

EU CHMP issued a second negative opinion on Omeros' marketing authorization for narsoplimab, blocking European launch.

Expected impact

likely pressure as investors price in the regulatory setback

Evidence & confidence

Regulatory denial is a material catalyst; no alternative EU pathway disclosed.

Market effects

Sector

Biotech firms with similar complement pathway drugs may see heightened scrutiny.

Regional

European biotech market may see reduced optimism for US firms seeking EMA approval.

Global

Limited to Omeros and niche TA‑TMA therapy market.

Counterpoint

What could challenge this read

The company could pivot to compassionate‑use sales in Europe, mitigating revenue loss.

Key entities

  • company
    Omeros Corporation

    Biopharma developing narsoplimab for TA‑TMA.

  • regulatory_body
    CHMP (EMA)

    European Medicines Agency committee issuing the negative opinion.

Read at source← All news

StoryEMA CHMP upholds negative opinion on Omeros’ narsoplimab, EU compassionate‑use program to end

Also covered by

5 outlets

Related articles

OCT 16
$OMERHighAI 8/10

Why is Omeros stock sliding today?

Omeros (OMER) stock fell 5.4% in pre-market trading after the European Medicines Agency's committee issued a second negative opinion on its Yartemlea drug application. The company will end its European compassionate-use program and abandon plans to license EU commercialization rights. Insiders sold $3M in shares over the past year. The stock traded at $17.77, down from $18.79. The U.S. launch of Yartemlea remains on track, with next earnings expected in mid-November.

investing.com2 min
OCT 16
$OMERHighAI 8/10

Omeros shares slide following European regulatory setback for Narsoplimab

Omeros Corporation (NASDAQ: OMER) shares fell 4% after the European Medicines Agency's CHMP maintained a negative opinion on its drug narsoplimab for treating TA-TMA, despite U.S. FDA approval. The decision followed a re-examination and expert review, contrasting with the drug's success in the U.S. Omeros plans to terminate its European compassionate-use program and continues clinical studies for other conditions.

investing.com2 min